The rise of theranostics: Part 4 -- Women's theranostics on the horizon
AuntMinnie
JULY 8, 2024
Gayton oversees clinical operations at Precirix and serves as the company's chief development officer. Twenty of the 26 scans from patients with active tumors were NeoB-positive, six NeoB-negative. Both groups would undergo standard of care imaging, or CT and bone scan, or FDG PET/CT, or FES PET/CT.
105 
Let's personalize your content